Remimazolam and Postoperative Nausea and Vomiting in High-risk Patients

• Status: Recruiting
• Trial end date: 2022-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial aims to explore whether the intraoperative use of remimazolam can reduce the incidence of postoperative nausea and vomiting (PONV) in high-risk patients. According to the Apfel's simplified score, patients with 3 or more of the following factors are at high risk of postoperative nausea and vomiting (PONV), i.e., women, non-smokers, history of PONV, and postoperative use of opioids.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking University First Hospital

Criteria

Inclusion Criteria:

1. Age ≥18 years old;

2. Scheduled to undergo elective surgery under general anesthesia;

3. Judged to be at high risk of postoperative nausea and vomiting. According to the Apfel's simplified score, patients with 3 or more of the following factors are at high-risk: women, non-smokers, history of PONV, postoperative use of opioids.

Exclusion Criteria:

1. Refuse to participate;

2. Previous history of schizophrenia, epilepsy, Parkinson's disease or myasthenia gravis;

3. Severe liver dysfunction (Child-Pugh class C);

4. Severe renal dysfunction (dialysis required);

5. Patients of the American Society of Anesthesiologists (ASA) grade 4 and above;

6. Emergency surgery;

7. Continuously taking benzodiazepines for more than 1 week before surgery;

8. Any other circumstances that are considered unsuitable for study participation by attending physicians or investigators.